Spectrum Pharmaceuticals (Nasdaq:SPPI) - Cours de l'action, nouvelles et analyse

SPPI Aperçu des actions

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. Plus de détails

SPPI analyse fondamentale
Score flocon de neige
Évaluation	6/6
Croissance future	5/6
Performances passées	0/6
Santé financière	3/6
Dividendes	0/6

Récompenses

Se négocie à 82.9% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 67.27% par an

Se négocie à un bon prix par rapport à ses pairs et au secteur

Les analystes s'accordent à dire que le prix des actions augmentera de 22.3%

Analyse des risques

Les actionnaires ont été dilués au cours de l'année écoulée

A moins d'un an de piste de trésorerie

Spectrum Pharmaceuticals, Inc. Concurrents

Gossamer Bio

NasdaqGS:GOSS

US$157.6m

Zentalis Pharmaceuticals

NasdaqGM:ZNTL

US$230.2m

Monte Rosa Therapeutics

NasdaqGS:GLUE

US$521.6m

Invivyd

NasdaqGM:IVVD

US$83.9m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Spectrum Pharmaceuticals
Historique des cours de bourse
Prix actuel de l'action	US$1.03
Plus haut sur 52 semaines	US$1.57
Plus bas sur 52 semaines	US$0.32
Bêta	2.14
1Variation sur 1 mois	4.54%
Variation sur 3 mois	-1.90%
Variation sur 1 an	17.05%
3Variation sur 3 ans	-71.39%
Variation sur 5 ans	-95.10%
Évolution depuis l'introduction en bourse	-99.25%

Nouvelles et mises à jour récentes

Recent updates

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

May 14

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

May 12

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

Sep 20

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Sep 16

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Sep 09

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

Aug 21

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Aug 10

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Jun 04

Spectrum Pharmaceuticals: Some Last Words

Feb 25

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Oct 05

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

May 31

We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate

Feb 12

Spectrum Pharma drops after announcing less-than-favorable Phase 2 data

Dec 22

Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like

Dec 21

Spectrum Pharma Is Down But Not Out

Nov 16

Spectrum Shareholders In Limbo As FDA Delays Rolontis Decision Date, Agrees To Discuss Poziotinib

Nov 11

Rendement pour les actionnaires

	SPPI	US Biotechs	US Marché
7D	5.3%	2.5%	2.2%
1Y	17.0%	16.1%	31.6%

Rendement vs Industrie: SPPI a dépassé le secteur US Biotechs qui a rapporté 16.1 % au cours de l'année écoulée.

Rendement vs marché: SPPI a dépassé le marché US qui a rapporté 31.6 % au cours de l'année écoulée.

Volatilité des prix

Is SPPI's price volatile compared to industry and market?
SPPI volatility
SPPI Average Weekly Movement	7.2%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Cours de l'action stable: Le cours de l'action de SPPI a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de SPPI a diminué de 15% à 7% au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1987	86	Tom Riga	www.sppirx.com

Spectrum Pharmaceuticals, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Spectrum Pharmaceuticals se comparent-ils à sa capitalisation boursière ?
SPPI statistiques fondamentales
Capitalisation boursière	US$209.89m
Bénéfices(TTM)	-US$67.71m
Recettes(TTM)	US$25.73m

8.2x

Ratio P/S

-3.1x

Ratio P/E

Le site SPPI est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
SPPI compte de résultat (TTM)
Recettes	US$25.73m
Coût des recettes	US$2.86m
Marge brute	US$22.87m
Autres dépenses	US$90.58m
Les revenus	-US$67.71m

Derniers bénéfices déclarés

Mar 31, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-0.33
Marge brute	88.90%
Marge bénéficiaire nette	-263.16%
Ratio dettes/capitaux propres	107.6%

Quelles ont été les performances à long terme de SPPI?

Voir les performances historiques et les comparaisons

SPPI Aperçu des actions

Récompenses

Analyse des risques

Spectrum Pharmaceuticals, Inc. Concurrents

NasdaqGS:GOSS

US$157.6m

NasdaqGM:ZNTL

US$230.2m

NasdaqGS:GLUE

US$521.6m

NasdaqGM:IVVD

US$83.9m

Historique des prix et performances

Nouvelles et mises à jour récentes

Spectrum Pharmaceuticals, Inc. Files Form 15

Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from NASDAQ Composite Index

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Consensus estimates of losses per share improve by 38%

Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 23%

Recent updates

Spectrum Pharmaceuticals, Inc. Files Form 15

Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from NASDAQ Composite Index

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Consensus estimates of losses per share improve by 38%

Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 23%

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

Price target decreased by 33% to US$1.26

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

Forecast breakeven date moved forward to 2024

Consensus EPS estimates upgraded to US$0.17 loss

Price target decreased by 15% to US$2.65

Spectrum Pharmaceuticals, Inc. Receives Permanent J-Code for ROLVEDON Injection (J1449) from U.S. Centers for Medicare & Medicaid Services

President notifies of intention to sell stock

Consensus revenue estimates increase by 161%

Spectrum Pharmaceuticals, Inc. Provides Sales Guidance for the Quarter Ended December 31, 2022

Spectrum Pharmaceuticals Announces Executive Changes

Forecast to breakeven in 2025

Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Spectrum Pharmaceuticals, Inc

Spectrum Pharmaceuticals’ ROLVEDON™ Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors

Consensus revenue estimates increase by 16%

Spectrum Pharmaceuticals, Inc. Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection

Price target decreased to US$3.10

Price target decreased to US$4.13

Spectrum Pharmaceuticals Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Spectrum Pharmaceuticals Announces Commercial Availability of Rolvedon™ (Eflapegrastim-Xnst) Injection

No longer forecast to breakeven

Spectrum Pharmaceuticals, Inc. Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting

Price target decreased to US$5.40

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Consensus forecasts updated

Spectrum Pharmaceuticals Receives Food and Drug Administration Approval for ROLVEDON (eflapegrastim-xnst) Injection

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

Consensus revenue estimates fall by 61%

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Spectrum Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Consensus forecasts updated

Spectrum Pharmaceuticals, Inc. Appoints Nora E. Brennan as Chief Financial Officer

Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to its Board of Directors

Price target decreased to US$5.60

Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim

Price target decreased to US$5.60

Spectrum Pharmaceuticals: Some Last Words

Spectrum Pharmaceuticals, Inc. Announces Resignation of Kurt Gustafson as Chief Financial Officer

Spectrum Pharmaceuticals, Inc. Announces Acceptance of New Drug Application Filing for Poziotinib

Spectrum Pharmaceuticals Announces Strategic Restructuring

Forecast to breakeven in 2024

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Spectrum Pharmaceuticals, Inc. Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at European Society for Medical Oncology Congress 2021

Pomerantz LLP Announces the Filing of Class Action Against Spectrum Pharmaceuticals, Inc and Certain Officers

Consensus revenue estimates fall to US$2.30m

Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity

Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for ROLONTIS® (eflapegrastim)

No longer forecast to breakeven

Price target decreased to US$9.40

High number of new directors